With Refills, the important care-delivery question is not simply whether a prescription can reach your door. It is who evaluates your health history, who chooses the medicine, which pharmacy fills it and whom you contact when something changes. Refills presents those steps through one digital experience, but its legal documentation separates the technology platform from the independent clinical and pharmacy organizations responsible for treatment and dispensing. That distinction matters before enrollment, not just when a problem occurs.
This review examines Refills’ public documentation consulted October 19, 2026, following the pathway from intake through repeat prescriptions. The company advertises injectable compounded GLP-1 and personalized GIP + GLP-1 options, starting-price promotions and ongoing support. It also publishes terms that qualify some simpler marketing statements. The resulting picture is a documented virtual service with identifiable partners, but not a fully specified purchase: the exact product, checkout charge, service availability and follow-up arrangements still need confirmation for the individual plan.
At a glance
- Platform, not the treating organization
- Refills Health LLC operates the digital properties; Refills describes independent clinicians working through partners including Beluga Health, Bask Health, Wasef Health and TelegraMD.
- Documented injectable options
- The GLP-1 page identifies compounded semaglutide. The personalized GIP + GLP-1 injection page does not identify its specific active ingredient in the consulted description.
- Starting price is not a checkout total
- Both product pages advertise prices as low as $5 per day, without establishing the total charge, billing period or supply duration in those advertisements.
- Delivery clock starts after earlier steps
- The FAQ says most orders arrive within 3–5 business days after prescription approval and pharmacy processing, not within that period after signup.Sources: [5]
One website, several organizations with different responsibilities
Refills Health LLC operates the websites and digital services, according to its terms. The homepage separately states that Refills Health is a technology platform, not a medical services provider. It names Beluga Health, Bask Health, Wasef Health and TelegraMD as clinical partners; the terms specifically identify Wasef Health, P.C. among the professional entities. These disclosures offer a useful starting point for distinguishing the company collecting enrollment information from the organization actually providing medical care.
The website assessment does not itself establish a clinician–patient relationship with Refills Health. Prescribing decisions belong to the independent clinician rather than the platform. Consequently, an attractive product page or completed questionnaire is not a prescription guarantee. Before submitting payment, ask which professional entity will handle the consultation and where its clinical messages will appear. Our guide to clinicians and telehealth platforms explains why these separate roles can affect communication and accountability.
The public contact page lists support at (888) 458 5061 and a business address at 1401 Pennsylvania Avenue, Suite 105, Wilmington, Delaware 19806. Those are administrative contact details, not evidence of an in-person treatment location. Refills’ privacy policy also says it collects sensitive information about health conditions and medications, including weight-management and reproductive or sexual health information. Enrollment therefore involves both a clinical handoff and disclosure of substantial personal health information.
| Stage | Documented responsibility | What to confirm |
|---|---|---|
| Account and enrollment | Refills operates the digital platform | Where billing and account questions go |
| Evaluation and prescribing | Independent clinicians through professional entities | The treating entity and clinical contact route |
| Dispensing | Outside pharmacy partners or a chosen pharmacy | The assigned pharmacy and exact preparation |
| Shipment | Delivery follows approval and pharmacy processing | Processing time, tracking and temperature concerns |
| Ongoing care | Care-team access and plan-dependent clinical messaging | Check-in schedule and medical response expectations |
Intake is virtual, but approval and availability remain conditional
Refills describes a fully virtual process without required in-person visits or insurance. The intake asks about health history, lifestyle and weight-loss goals; a licensed clinician reviews the information and may order laboratory testing if needed. The terms require users to be at least 18. The advertised three-minute quiz should therefore be understood as an entry point, not the duration of a complete medical evaluation or a promise that medication will be prescribed.
The FAQ says clinicians consider BMI and weight history, weight-related conditions, current medicines, contraindications and previous weight-loss efforts. It does not establish a numerical BMI cutoff in the consulted passage. The product page lists personal or family history of medullary thyroid cancer or MEN2, a serious allergic reaction to the medication, and certain pregnancy or breastfeeding situations as possible reasons someone may not be eligible. It also says specific gastrointestinal conditions or prior pancreatitis may require extra caution; the clinician determines individual suitability. Timing is also presented in two different ways: requests are often reviewed within hours, depending on demand and state coverage, while the homepage places the initial consultation within a few days of signup. A request review and a completed consultation should not be treated as interchangeable milestones.
Geography needs direct confirmation. The homepage says Refills operates in all 50 states but excludes the District of Columbia; the terms include both all 50 states and D.C. and limit services to people located in the United States. The FAQ adds that treatment availability depends on professional coverage and that shipping reaches most states, subject to product and pharmacy rules. Ask about the exact treatment at your current location rather than relying on the broadest nationwide statement.
Identify the actual prescription before evaluating the offer
The GLP-1 product page identifies its compounded option as compounded semaglutide and presents it as an injectable treatment. A separate page advertises a personalized GIP + GLP-1 injection plan, but the consulted description does not identify the active ingredient. The FAQ mentions semaglutide-based and liraglutide-based options as examples of the GLP-1 category. That category language does not establish that a particular liraglutide product is available to every applicant or in every state.
Refills says its GLP-1 medicines come exclusively from U.S. pharmacies and that a partner clinician may prescribe a compounded medicine when medically appropriate. Its product disclosure states that compounded drugs are not FDA approved or evaluated by FDA for safety, effectiveness or quality. FDA recommends compounded drugs when a patient’s medical needs cannot be met by an approved drug, with a prescription and a state-licensed pharmacy. This is product-level regulatory context, not FDA approval or rejection of Refills itself.
Before accepting a plan, obtain the ingredient, formulation, route, presentation and dispensing pharmacy in writing. The absence of FDA approval alone does not establish clinical inequivalence, but neither do familiar ingredient names establish equivalence to an approved product. The consulted materials do not independently verify Refills’ formulations. Our product and formulation checklist offers a framework for separating a category label from the preparation actually prescribed, without substituting a review for the clinician’s decision.
The pharmacy handoff offers names, but not a guaranteed assignment
The pharmacy-partner page identifies Perfect Rx Pharmacy, operated by PERFECTRX LLC in Bartonville, Texas, and Hallandale Pharmacy, operated by Pharmcore, Inc. in Fort Lauderdale, Florida. The terms list a broader network that also includes Greenwich Pharmacy, VialsRx and The Pharmacy Hub. These names make the dispensing structure more concrete than an unnamed pharmacy network, but a partner list does not identify which organization will fill a particular person’s prescription.
The terms say that, if a clinician issues a prescription, the patient may use an accessible network pharmacy or request that it be sent to a pharmacy of their choice. That is a meaningful documented option, although the consulted materials do not establish that every outside pharmacy can fulfill every preparation or preserve the advertised package price. Confirm fulfillment and pricing before requesting a transfer, rather than assuming the platform’s offer follows the prescription unchanged.
Refills says pharmacy partners are vetted, medication batches undergo purity and potency testing, and patients can request a Certificate of Analysis at any time. These are provider claims; this review did not independently verify licenses or inspect a prescription-specific certificate. Ask which pharmacy compounded or dispensed the preparation and how to obtain the relevant testing documentation. The pharmacy handoff guide describes questions that help connect the prescription, dispensing label and pharmacy contact information.
Delivery begins after approval and pharmacy processing
Refills’ FAQ says most orders arrive within three to five business days after prescription approval and pharmacy processing. This is an arrival estimate with conditions, not a signup-to-door guarantee. The documentation does not specify how long pharmacy processing takes, so the advertised review window cannot simply be added to the shipping estimate to produce a reliable total. Refills says tracking becomes available when the order ships, which provides a separate milestone from approval.
The FAQ describes plain, unbranded outer packaging with no indication of the contents. The terms add a different packaging issue: pharmacy-fulfilled products may not arrive in child-resistant packaging or containers. Meanwhile, the consulted documentation does not establish the carrier, cold-chain procedures, or specific replacement and reimbursement rules for lost packages. Those questions deserve answers from the assigned pharmacy or support team before shipment, especially when coordinating receipt of an injectable medicine.
FDA explicitly recommends not using an injectable GLP-1 drug that arrives warm or with insufficient refrigeration, and contacting the provider or dispensing pharmacy to resolve the concern. That advice should not be replaced by assumptions based on an intact outer box or a delivery estimate. Our guide to warm injectable deliveries explains that distinction. Refills’ public shipping statements do not establish how any individual temperature concern will be assessed or remedied.
Ongoing support is not the same as continuous clinical availability
The how-it-works page promises ongoing care-team access through the dashboard for questions and treatment adjustments. The homepage advertises free 24/7 Health Concierge support. The FAQ makes an important distinction: account, shipping and billing issues go through nonmedical support, while side effects and prescription guidance belong in the clinical messaging pathway, if available under the plan. Taken together, these statements do not establish around-the-clock access to a prescribing clinician or a guaranteed medical response time.
A full consultation is not necessarily repeated every month. Refills says many subscriptions use clinician involvement at appropriate check-in points, with additional review potentially needed for new symptoms, treatment changes, medical history or laboratory results. Its weight-management page also describes clinician assistance with moving from active weight loss to maintenance. What remains unclear is the mandatory check-in cadence, the scope of included clinical messaging and whether particular reviews or tests create additional charges.
This distinction matters because renewal payments alone do not document clinical monitoring. NIDDK describes follow-up as assessing tolerance and response, with treatment duration depending on benefits and side effects. FDA also reports errors measuring or administering compounded medicines, including some associated with hospitalization. Patients should clarify instructions with the prescriber or pharmacist rather than calculate doses from an article. For Refills specifically, establish the medical contact route and escalation process before the first delivery.
The financial handoff needs more detail than a daily starting price
Both injectable product pages advertise prices as low as $5 per day and free shipping. Those advertisements do not establish a purchase total, billing interval, supply quantity or commitment. The homepage also displays a 40% discount without explaining its reference price, duration or eligibility in the consulted material. Refills says actual cost depends on the medication, prescribed plan and state availability. No monthly or annual total can responsibly be derived from the daily starting figure alone.
The homepage says there are no monthly membership or app fees and that all dosages have the same price. The terms, however, say the total subscription price includes pharmacy charges, professional-service charges and applicable platform-access fees. These may be differently described components rather than separate additional charges, but the documentation does not reconcile them. Ask for an itemized checkout total, what the first payment covers, later charges and whether any laboratory work is separate.
Insurance statements also require clarification. The service advertises that insurance is not required, while the terms establish direct payment and prohibit seeking reimbursement from federal, state or private payor programs for products and services through this pathway. The FAQ nevertheless leaves open possible insurance involvement for specific medicines or fulfillment routes. Do not assume insurance reimbursement is available. Obtain confirmation of the applicable pathway, and note that the FAQ promises free shipping on most refills, not necessarily every refill.
Plan the next refill—and the exit—before the first charge
The terms authorize automatic recurring charges at the intervals disclosed during checkout until cancellation. Although the FAQ describes subscriptions as having no long-term commitments and allowing pauses, skips or cancellation anytime, the terms impose a specific operational deadline: cancel at least 72 hours before the applicable monthly processing date. They allow cancellation through app.refills.com or email, but the email address was not readable in the consulted text. The account portal is the clearly documented usable route.
The FAQ promises an email reminder before each upcoming charge. That reminder does not replace knowing the processing date or meeting the contractual cutoff. Save the checkout schedule and any cancellation confirmation, and ask how a pause affects a prescription already being processed. The consulted documentation does not establish the contents of a refund or return policy. Canceling future renewals should therefore not be interpreted as a promise to refund an existing charge or a dispensed prescription.
Questions & answers
Will Refills itself be my medical provider?
Refills describes itself as a technology platform connecting patients with independent clinicians, not the medical services provider. Its terms identify professional entities involved in care, including Wasef Health, P.C. Ask which entity will treat you and where its clinical messages are handled. Completing the platform’s assessment does not create a clinician–patient relationship with Refills Health itself.
Does the GIP + GLP-1 offer confirm a particular medicine?
Not in the consulted product description. It identifies a personalized GIP + GLP-1 injection plan without naming the specific active ingredient. By contrast, the GLP-1 page identifies compounded semaglutide. Ask for the exact ingredient, formulation, presentation and pharmacy before evaluating the offer; a dual-pathway category label is not a complete prescription description.
Can I use a pharmacy outside Refills’ network?
The terms allow a prescription, if issued, to be sent to a pharmacy of your choice instead of a network pharmacy. They do not establish that every pharmacy can supply the particular preparation or that the platform’s advertised price carries over. Confirm availability, pharmacy charges and how clinical questions will be coordinated before choosing that route.
Is Refills available in Washington, D.C.?
The consulted pages conflict: the homepage excludes D.C., while the terms include it. The FAQ further qualifies availability by treatment, professional coverage and pharmacy rules. D.C. residents should obtain direct confirmation for the exact proposed treatment and dispensing route. The broad national statements do not resolve whether a particular application can proceed.
Does the daily starting price include every care expense?
The $5-per-day advertisement does not specify a complete purchase total or billing period. The terms describe a total subscription price incorporating medication, professional services and applicable platform fees, but laboratory costs are not established. Get the actual first charge, renewal amount, supply duration and any separate testing costs before treating the advertisement as a budget.
Can I cancel on the day my subscription processes?
Do not rely on the FAQ’s broad anytime-cancellation wording for that situation. The terms require cancellation at least 72 hours before the applicable monthly processing date. They identify the account portal as a cancellation route. Public documentation does not establish that cancellation produces a refund, so ask separately about any payment already collected or prescription already in processing.
Our assessment
Refills provides a recognizable virtual care pathway: online intake, independent clinical review, outside pharmacy fulfillment, tracked delivery and dashboard-based support. Naming clinical and pharmacy partners, acknowledging compounded-product limitations and allowing a chosen pharmacy are useful disclosures. The documentation is less settled at the boundaries between those stages. State coverage conflicts, the unidentified ingredient in the dual-pathway offer, incomplete purchase pricing and uncertain clinical response expectations deserve resolution before enrollment. A practical decision should rest on a written plan identifying the treating entity, exact prescription, dispensing pharmacy, full charges, follow-up route and cancellation date—not on the quiz length, daily starting price or concierge availability alone.
This opens the reviewed business’s website. The link is not a prescription or endorsement. Commercial relationships.
Sources & documentation
Public materials consulted October 19, 2026. Provider statements are attributed claims, not independently verified clinical outcomes. Terms can change; obtain a current written quote.
- FDA concerns with unapproved GLP-1 drugs used for weight loss ↗
- NIDDK: prescription medications for overweight and obesity ↗
- Refills / Refills Health — privacy policy ↗
- Refills / Refills Health — official website ↗
- Refills / Refills Health — faq ↗
- Refills / Refills Health — terms conditions ↗
- Refills / Refills Health — our pharmacy partner ↗
- Refills / Refills Health — weight loss ↗
- Refills / Refills Health — weight loss/personalized glp 1 injection ↗
- Refills / Refills Health — weight loss/personalized gip glp 1 injection ↗
- Refills / Refills Health — how refills works ↗
- Refills / Refills Health — contact ↗